Cytolysis of tumor cells and enhanced antibody-dependent cellular cytotoxicity.

Anadys Pharmaceuticals presents data showing ANA773 promotes anti-tumor activity of killer cells Anadys Pharmaceuticals presented data from an in vitro research showing that the active metabolite of ANA773 promotes normal killer cell-mediated anti-tumor response by inducing cytokine secretion, cytolysis of tumor cells and enhanced antibody-dependent cellular cytotoxicity , throughout a poster presentation at the Annual Conference of the American Association of Malignancy Research in Los Angeles . The scholarly study discovered that the active metabolite of ANA773, an oral Toll-like receptor 7 agonist prodrug, induced the secretion of interferon-alpha and different other cytokines from individual peripheral bloodstream mononuclear cells cultured in vitro.

And its affiliates, BioMed Ventures, Cormorant Asset Management, Frazier Healthcare, HBM Healthcare Investments, Longwood Capital Partners, Novo A/S and additional undisclosed investors. Arises from the funding are designed to advance AnaptysBio's first-in-course anti-IL-36 and anti-IL-33 receptor antibody programs through key Phase II studies. The financing may also support the continuing discovery of novel therapeutic antibodies against emerging focus on biology in inflammation and immuno-oncology using AnaptysBio's proprietary somatic hypermutation-based antibody discovery platform.